Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

about

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

Item

http://www.wikidata.org/entity/Q36278006

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

@ast

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

@en

type

Item

label

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

@ast

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

@en

prefLabel

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

@ast

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

@en

P1476

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

@en

P2093

Nishanth Vallumsetla

http://www.w3.org/2001/XMLSchema#string

Prashant Kapoor

http://www.w3.org/2001/XMLSchema#string

P2860

Advances in the understanding of mechanisms and therapeutic use of bortezomib

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

P304

1663-1674

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S72943

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jonas Paludo

P577

2015-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26609233

http://www.w3.org/2001/XMLSchema#string

P932

4644179

http://www.w3.org/2001/XMLSchema#string